中华眼底病杂志

中华眼底病杂志

糖尿病视网膜病变筛查意义及操作指南

查看全文

糖尿病视网膜病变(DR)是工作年龄人群中发生可预防性失明的最常见原因。除优化控制高血糖、高血压、高血脂等危险因素外,定期对糖尿病患者进行眼底筛查,对于早期发现尚无明显视觉症状的视网膜病变,及时治疗威胁视力的视网膜病变,从而降低DR导致的失明和严重的视力损伤至关重要。目前全球各医学会指南均建议对糖尿病患者进行定期视网膜病变筛查,但国内外指南对于DR筛查的起始时间、筛查间隔、筛查工具及随访转诊意见存在不一致的问题。详细了解目前各个地区明确提出的DR筛查指南意见及其临床依据具有重要的临床意义。

Diabetic retinopathy (DR) is the most common cause of preventable blindness in the working-age population. In addition to optimizing the hyperglycemia, hypertension, hyperlipidemia and other risk factors, regular fundus examination is essential for early diagnosis asymptomatic DR and timely treat the sight-threatening DR, so as to reduce blindness and severe visual impairment caused by DR. Clinical practice guidelines for the screening and management of DR have been implemented throughout the world, but there are reasonable differences between existing guidelines in the recommended timing of first retinal examination, screening intervals, methods for examination and criteria for referral to an ophthalmologist. It is of great clinical significance to have a detailed understanding of the current guidelines for DR screening and their clinical basis.

关键词: 糖尿病视网膜病变; 指南; 综述; 筛查

Key words: Diabetic retinopathy; Guidebooks; Review; Screening

引用本文: 李淑婷, 王相宁, 吴强. 糖尿病视网膜病变筛查意义及操作指南. 中华眼底病杂志, 2019, 35(2): 200-206. doi: 10.3760/cma.j.issn.1005-1015.2019.02.019 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2[J]. Arch Ophthalmol, 1985, 103(11): 1644-1652. DOI: 10.1001/archopht.1985.01050110038020.
2. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9[J]. Ophthalmology, 1991, 98(5 Suppl): S766-785.
3. Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema[J/OL]. Cochrane Database Syst Rev, 2014, 10(10): CD007419[2014-10-24]. https://doi.org/10.1002/14651858.CD007419.pub4. DOI: 10.1002/14651858.CD007419.pub4.
4. Paz SH, Varma R, Klein R, et al. Noncompliance with vision care guidelines in Latinos with type 2 diabetes mellitus: the Los Angeles Latino Eye Study[J]. Ophthalmology, 2006, 113(8): 1372-1377. DOI: 10.1016/j.ophtha.2006.04.018.
5. Lee DJ, Kumar N, Feuer WJ, et al. Dilated eye examination screening guideline compliance among patients with diabetes without a diabetic retinopathy diagnosis: the role of geographic access[J/OL]. BMJ Open Diabetes Res Care, 2014, 2(1): 000031 [2014-08-23]. http://dx.doi.org/10.1136/bmjdrc-2014-000031. DOI: 10.1136/bmjdrc-2014-000031.
6. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial[J]. Ophthalmology, 1995, 102(4): 647-661. DOI: 10.1016/S0161-6420(95)30973-6.
7. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors[J]. Arch Ophthalmol, 1998, 116(3): 297-303. DOI: 10.1001/archopht.116.3.297.
8. Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[J]. Ophthalmology, 2014, 121(12): 2443-2451. DOI: 10.1016/j.ophtha.2014.07.019.
9. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes[J]. N Engl J Med, 2010, 363(3): 233-244. DOI: 10.1056/NEJMoa1001288.
10. Jin P, Peng J, Zou H, et al. A five-year prospective study of diabetic retinopathy progression in chinese type 2 diabetes patients with "well-controlled" blood glucose[J/OL]. PLoS One, 2015, 10(4): 0123449[2015-04-07]. http://dx.plos.org/10.1371/journal.pone.0123449. DOI: 10.1371/journal.pone.0123449.
11. Clinical practice guidelines: directions for a new program[M]. Washington (DC): National Academies Press (US), 1990.
12. Ferris FL. How effective are treatments for diabetic retinopathy?[J]. JAMA, 1993, 269(10): 1290-1291. DOI: 10.1001/jama.1993.03500100088034.
13. World Health Organization. Prevention of blindness from diabetes mellitus: report of a WHO consultation in Geneva, Switzerland[EB/OL].[2005-11-11]. http://www.who.int/iris/handle/10665/43576.
14. International Concil Ophthalmology. ICO guidelines for diabetic eye care[EB/OL].[2017-04-01]. http://www.icoph.org/enhancing_eyecare/diabetic_eyecare.html.
15. Ophthalmology AAO. Preferred practice pattern: diabetic retinopathy[EB/OL]. [2016-05-01]. http://www.aaojournal.org/content/preferred-practice-pattern.
16. Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association[J]. Diabetes Care, 2017, 40(3): 412-418. DOI: 10.2337/dc16-2641.
17. Hooper P, Boucher MC, Cruess A, et al. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy[J]. Can J Ophthalmol, 2012, 47(2 Suppl): S1-54. DOI: 10.1016/j.jcjo.2011.12.025.
18. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada[J]. Can J Diabetes, 2013, 37 Suppl 1: S137-141.
19. NICE Guideline. Diabetes (type 1 and type 2) in children and young people: diagnosis and management[EB/OL]. [2015-08-01]. https://www.nice.org.uk/guidance/ng18.
20. NICE Guideline. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period[EB/OL]. [2015-02-01]. https://www.nice.org.uk/guidance/ng3.
21. NICE Guideline. Type 1 diabetes in adults: diagnosis and management[EB/OL]. [2015-08-01]. https://www.nice.org.uk/guidance/ng17.
22. NICE Guideline. Type 2 diabetes in adults: management[EB/OL]. [2015-12-01]. https://www.nice.org.uk/guidance/ng28.
23. The Royal College of Ophthalmologists Diabetic Retinopathy Guidelines[EB/OL]. [2013-01-01]. https://www.rcophth.ac.uk/clinicalguidelines.
24. Scottish Intercollegiate Guidelines Network. Management of diabetes--a national clinical guideline[EB/OL]. [2017-01-01]. https://www.sign.ac.uk/our-guidelines.html.
25. NHMRC. Guidelines for the management of diabetic retinopathy[EB/OL]. [2008-01-01]. https://www.nhmrc.gov.au/guidelines-publications/cp53.
26. New Zealand Pacific Eye Institute. Diabetes retinal screening, grading and management guidelines for use in Pacific Island Nations[EB/OL]. [2016-03-18]. https://www.health.govt.nz/publication/diabetic-retinal-screening-grading-monitoring-and-referral-guidance.
27. 中华医学会眼科学分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.Ophthalmology Branch of Chinese Medical Association. Guidelines for clinical diagnosis and treatment of diabetic retinopathy in China[J]. Chin J Ophthalmol, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.
28. Ministry of Health. Clinical practice guidelines: screening of diabetic retinopathy[EB/OL]. [2011-01-01]. http://www.moh.gov.my/index.php/pages/view/161.
29. Department of Health (National). National guideline: prevention of blindness in South Africa[EB/OL]. [2011-01-01]. https://www.westerncape.gov.za/your_gov/55/documents/guides.
30. VISION 2020. Guidelines for diabetic eye care in India[EB/OL]. [2015-01-01]. http://www.icoph.org/resources/327/Guidelines-for-Diabetic-Eye-Care-in-India.html.
31. System Aec. Guidelines for the comprehensive management of diabetic retinopathy in India. A VISION 2020: The Right to Sight INDIA Publication[EB/OL]. [2008-01-01]. https://www.iapb.org/.
32. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy.Ⅱ. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years[J]. Arch Ophthalmol, 1984, 102(4): 520-526. DOI: 10.1001/archopht.1984.01040030398010.
33. Varma R, Torres M, Peña F, et al. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino Eye Study[J]. Ophthalmology, 2004, 111(7): 1298-1306. DOI: 10.1016/j.ophtha.2004.03.002.
34. Klein R, Davis MD, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. A comparison of retinopathy in younger and older onset diabetic persons[J]. Adv Exp Med Biol, 1985, 189: 321-335. DOI: 10.1007/978-1-4757-1850-8.
35. Klein R, Klein BE, Moss SE, et al. Retinopathy in young-onset diabetic patients[J]. Diabetes Care, 1985, 8(4): 311-315. DOI: 10.2337/diacare.8.4.311.
36. Harris M, Klein R, Welborn T, et al. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis[J]. Diabetes Care, 1992, 5(7): 815-819. DOI: 10.2337/diacare.15.7.815.
37. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ⅲ. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years[J]. Arch Ophthalmol, 1984, 102(4): 527-532. DOI: 10.1001/archopht.1984.01040030405011.
38. Heath V. Diabetes: progression of diabetic retinopathy found to be a potential risk during pregnancy[J]. Nat Rev Endocrinol, 2010, 6(7): 354. DOI: 10.1038/nrendo.2010.73.
39. Morrison JL, Hodgson LA, Lim LL, et al. Diabetic retinopathy in pregnancy: a review[J]. Clin Exp Ophthalmol, 2016, 44(4): 321-334. DOI: 10.1111/ceo.12760.
40. Jones CD, Greenwood RH, Misra A, et al. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England[J]. Diabetes Care, 2012, 35(3): 592-596. DOI: 10.2337/dc11-0943.
41. Chalk D, Pitt M, Vaidya B, et al. Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy?[J]. Diabetes Care, 2012, 35(8): 1663-1668. DOI: 10.2337/dc11-2282.
42. Echouffo-Tcheugui JB, Ali MK, Roglic G, et al. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review[J]. Diabet Med, 2013, 30(11): 1272-1292. DOI: 10.1111/dme.12274.
43. Taylor-Phillips S, Mistry H, Leslie R, et al. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review[J]. Br J Ophthalmol, 2016, 100(1): 105-114. DOI: 10.1136/bjophthalmol-2014-305938.
44. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ⅸ. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years[J]. Arch Ophthalmol, 1989, 107(2): 237-243. DOI: 10.1001/archopht.1989.01070010243030.
45. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ⅹ. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more[J]. Arch Ophthalmol, 1989, 107(2): 244-249. DOI: 10.1001/archopht.1989.01070010250031.
46. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type Ⅱ diabetes over 6 years from diagnosis[J]. Diabetologia, 2001, 44(2): 156-163. DOI: 10.1007/s001250051594.
47. Ferris F. Early photocoagulation in patients with either type Ⅰ or type Ⅱ diabetes[J]. Trans Am Ophthalmol Soc, 1996, 94: 505-537.
48. Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes[J]. Diabetologia, 2010, 53(6): 1076-1083. DOI: 10.1007/s00125-010-1697-9.
49. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial[J]. Diabetes Care, 2000, 23(8): 1084-1091. DOI: 10.2337/diacare.23.8.1084.
50. Aspelund T, Thornórisdóttir O, Olafsdottir E, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy[J]. Diabetologia, 2011, 54(10): 2525-2532. DOI: 10.1007/s00125-011-2257-7.
51. Lund SH, Aspelund T, Kirby P, et al. Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs[J]. Br J Ophthalmol, 2016, 100(5): 683-687. DOI: 10.1136/bjophthalmol-2015-307341.
52. van der Heijden AA, Walraven I, van't Riet E, et al. Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy[J]. Diabetologia, 2014, 57(7): 1332-1338. DOI: 10.1007/s00125-014-3246-4.
53. Soto-Pedre E, Pinies JA, Hernaez-Ortega MC. External validation of a risk assessment model to adjust the frequency of eye-screening visits in patients with diabetes mellitus[J]. J Diabetes Complications, 2015, 29(4): 508-511. DOI: 10.1016/j.jdiacomp.2014.12.020.
54. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10[J]. Ophthalmology, 1991, 98(5 Suppl): S786-806.
55. Lairson DR, Pugh JA, Kapadia AS, et al. Cost-effectiveness of alternative methods for diabetic retinopathy screening[J]. Diabetes Care, 1993, 16(5): 1369-1377. DOI: 10.2337/diacare.15.10.1369.
56. Prasad S, Kamath GG, Jones K, et al. Effectiveness of optometrist screening for diabetic retinopathy using slit-lamp biomicroscopy[J]. Eye (Lond), 2001, 15(Pt 5): 595-601.
57. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
58. Javitt JC, Aiello LP, Bassi LJ, et al. Detecting and treating retinopathy in patients with type Ⅰ diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology[J]. Ophthalmology, 1991, 98(10): 1565-1573. DOI: 10.1016/S0161-6420(91)32086-4.
59. Moss SE, Klein R, Kessler SD, et al. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy[J]. Ophthalmology, 1985, 92(1): 62-67. DOI: 10.1016/S0161-6420(85)34082-4.
60. Pugh JA, Jacobson JM, Van Heuven WA, et al. Screening for diabetic retinopathy. The wide-angle retinal camera[J]. Diabetes Care, 1993, 16(6): 889-895. DOI: 10.2337/diacare.16.6.88.
61. Scanlon PH, Malhotra R, Greenwood RH, et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy[J]. Br J Ophthalmol, 2003, 87(10): 1258-1263. DOI: 10.1136/bjo.87.10.1258.
62. Hutchinson A, McIntosh A, Peters J, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy--a systematic review[J]. Diabet Med, 2000, 17(7): 495-506. DOI: 10.1046/j.1464-5491.2000.00250.x.
63. Williams GA, Scott IU, Haller JA, et al. Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2004, 111(5): 1055-1062. DOI: 10.1016/j.ophtha.2004.02.004.
64. Murgatroyd H, Ellingford A, Cox A, et al. Effect of mydriasis and different field strategies on digital image screening of diabetic eye disease[J]. Br J Ophthalmol, 2004, 88(7): 920-924. DOI: 10.1136/bjo.2003.026385.
65. Vujosevic S, Benetti E, Massignan F, et al. Screening for diabetic retinopathy: 1 and 3 nonmydriatic 45-degree digital fundus photographs vs 7 standard early treatment diabetic retinopathy study fields[J]. Am J Ophthalmol, 2009, 148(1): 111-118. DOI: 10.1016/j.ajo.2009.02.031.